Orient Pharma Co., Ltd.

Total Valuation

Orient Pharma Co., Ltd. carries a market capitalization of 6.29B, placing it among publicly traded companies globally. Its enterprise value stands at 5.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Orient Pharma Co., Ltd. currently has 243.04M shares outstanding.

Valuation Ratios

Orient Pharma Co., Ltd. trades at a trailing price-to-earnings ratio of 28.55. The price-to-sales ratio is 4.25, and the price-to-book ratio stands at 2.72.

Enterprise Valuation

On an enterprise value basis, Orient Pharma Co., Ltd. trades at an EV/EBITDA multiple of 20.67 and an EV/FCF ratio of 13.28. The EV/Sales ratio of 3.94 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.67 provides insight into valuation relative to core operating earnings.

Financial Position

Orient Pharma Co., Ltd. maintains a current ratio of 6.73, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.64, indicating elevated leverage, while an interest coverage ratio of 33.77 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Orient Pharma Co., Ltd. posts a return on equity of 14.68 and a return on invested capital of 8.93.

Taxes

Over the trailing twelve months, Orient Pharma Co., Ltd. has paid 36.21M in income taxes, reflecting an effective tax rate of 14.80.

Stock Price Statistics

Orient Pharma Co., Ltd.'s stock has declined approximately -29.61957% over the past 52 weeks. The 50-day moving average sits at 25.14, while the 200-day moving average is 25.57.

Income Statement

Over the trailing twelve months, Orient Pharma Co., Ltd. generated 1.40B in revenue and converted that into 208.44M in net income, yielding earnings per share of 0.92. EBITDA reached 267.06M, while operating income came in at 267.06M.

Balance Sheet

Orient Pharma Co., Ltd. holds 627.40M in cash and equivalents against 195.97M in total debt, resulting in a net debt position of -587.58M. Total book value stands at 2.19B, with working capital of 1.07B providing operational flexibility.

Cash Flow

Orient Pharma Co., Ltd. produced 359.86M in operating cash flow over the past twelve months. After subtracting -49.02M in capital expenditures, free cash flow totaled 310.84M - equivalent to 1.37 per share.

Margins

Orient Pharma Co., Ltd. operates with a gross margin of 56.46, reflecting its pricing power and cost economics. The operating margin of 19.07 and net profit margin of 14.88 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Orient Pharma Co., Ltd.'s most recent stock split took place on July 8, 2020 with a 500:541 split ratio.

Scores

Orient Pharma Co., Ltd. posts an Altman Z-Score of 10.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.